Among them, up-regulation of ATRX, PC, KDM2A and CARM1 featured a poor RiskStatus in AML progression and prognosis, while up-regulation of EZH2 and KDM5B in turn suggested a favorable RiskStatus feature (Figure 2B). Here, EZH2 is linked to acute myeloid leukemia.